Evidence map›Paper›PMID 39546228›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Psycho-Neuro-EndocrinE-Immunology Therapy of Cancer, Autoimmunity, Geriatric Disorders, Covid-19, and Hypertension.

Paolo Lissoni, Franco Rovelli, Giusy Messina, Alejandra Monzon, Agnese Valentini, Andrea Sassola, Giuseppe Di Fede, Ana Cristina Simoes-de-Silva, Nicoletta Merli, Christian Bartsch and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Paolo LissoniInstitute of Biological Medicine, Milan, Italy.ORCID 0000-0002-5374-1350
Franco RovelliInstitute of Biological Medicine, Milan, Italy.
Giusy MessinaInstitute of Biological Medicine, Milan, Italy.
Alejandra MonzonInstitute of Biological Medicine, Milan, Italy.
Agnese ValentiniInstitute of Biological Medicine, Milan, Italy.
Andrea SassolaFaculdade de Medicina, Belo Horizonte, Brazil.
Giuseppe Di FedeFaculdade de Medicina, Belo Horizonte, Brazil.
Ana Cristina Simoes-de-SilvaFaculdade de Medicina, Belo Horizonte, Brazil.
Nicoletta MerliUniversity of Tubingen, Tubingen, Germany.
Christian BartschUniversity of Tubingen, Tubingen, Germany.
Virgiliu Gheorghe VlaescuImmunomedica Institute, Bucuresti, Romania.
Daniel Diego CardinaliPontificia Universitad Catolica, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the great number of experimental investigations in the area of psycho-neuro-endocrine-immunology showing that endocrine, nervous, and immune systems cannot be in vivo physiologically separated, the diagnosis and therapies of the pathologies of these three functional biological systems continue to be separately performed from a clinical practice point of view. The separation between experimental and clinical medicine became dramatic after the discovery of more than 10 human molecules provided by anti-inflammatory and antitumor activity, completely devoid of any toxicity, which may be subdivided into three fundamental classes, consisting of the pineal indole, beta-carboline, and methoxy-kynuramine hormones. Moreover, human systemic diseases, including cancer, autoimmunity, and cardiovascular pathologies, despite their different pathogenesis and symptomatology, are commonly characterized by a progressive decline in the endogenous production of pineal hormones, endocannabinoids, and Ang 1-7, with a consequent inflammatory status and diminished natural resistance against cancer. Then the evaluation of the functional status of the pineal gland, the endocannabinoid system, and ACE2-Ang 1-7 axis should have to be included within the laboratory analyses for the systemic diseases. Finally, the correction of cancer- and autoimmunity-related neuroimmune and neuroendocrine alterations could influence the clinical course of systemic diseases. In fact, preliminary clinical results would demonstrate that the neuroimmune regimen with pineal hormones, cannabinoids, and Ang 1-7 may allow clinical benefits also in patients affected by systemic pathologies, including cancer, autoimmunity, and cardiovascular diseases, who did not respond to the standard therapies.

Indexed as

AutoimmunityCOVID-19HypertensionNeoplasmsSARS-CoV-2Angiotensin-Converting Enzyme 2Angiotensin IAutoimmune DiseasesEndocannabinoidsHumansPeptide FragmentsPineal GlandACE2 protein, humanAngiotensin-Converting Enzyme 2Angiotensin Iangiotensin I (1-7)EndocannabinoidsPeptide FragmentsAngiotensin 1-7CancerCannabinoidsInterleukinsMelatoninNeuroimmunomodulationPineal gland

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.